Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-6: Nemvaleukin Alfa ± Pembrolizumab in Advanced Melanoma
2024-513229-22-00Phase 2Completed
- Sponsor
- Mural Oncology
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label trial of nemvaleukin alfa and pembrolizumab in cutaneous melanoma (CM) and mucosal melanoma (MM) (4 cohorts), sponsored by Mural Oncology. Started Oct 2024; status: completed.
02
Drugs
nemvaleukin alfapembrolizumab
03
Conditions
cutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on 2024-513229-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513229-22-00.